Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Battle to beat the bugs wins bio-firm top honour

17.11.2005


A fledgling bio-business developing products to combat deadly hospital infections like MRSA has won a prestigious industry award.



Ai2, a University of Manchester spin-out company incorporated in April this year, took the Biotechnology Start-Up of the Year prize at the Northwest Regional Development Agency’s Bionow awards.

The company, set up by Dr Curtis Dobson in the University’s Faculty of Life Sciences, specialises in the development of novel antibacterial compounds.


“My work concerns chemicals called apolipovirs that have demonstrated both antimicrobial and antiviral qualities,” said Dr Dobson, who last year won Bionow’s Project of the Year for the same research.

“These compounds have been shown to be highly effective at killing bugs and so could have applications in the coating of medical devices and instruments.

“We also believe these chemicals could be developed into anti-fungal creams and barrier technologies in the fight against hospital infections like MRSA.”

But, says Dr Dobson, the first application for the anti-infective compounds is likely to be in the coating of contact lenses to prevent eye infections.

Longer-term, the company hopes the compounds can be developed into antiviral drugs that could treat diseases like HIV and hepatitis.

“In the lab, apolipovirs have been shown to attack the HIV virus before it can attach itself to the cell and so, in theory, could kill off the virus completely.

“This way of fighting viruses outside the cell has been overlooked in the past and so a lot more research is needed.

“Whether antiviral drugs will provide a cure on their own remains to be seen but that will be a focus of the next stage of our work.”

Dr Dobson’s studies stem from work he originally carried out with colleagues at the University that looked at the role viruses play in certain forms of dementia.

“It was through studying the interaction of human proteins with viruses that the apolipovir compounds were discovered.

“We found that a class of human proteins involved in immunity were rich in anti-infective activity, which has led to this powerful peptide-based antimicrobial technology.

“We have already developed compounds 10 times stronger than the original chemicals we tested and have filed four patent applications.

“We are now looking to put together a programme of further tests which will be the final stage of the pre-clinical work.”

The project is being managed by the University’s intellectual property company UMIP.

Project manager Gordon Barker said: “Ai2 aims to become a significant player in the global anti-infectives market by identifying unmet needs in the healthcare industry and rapidly developing novel products to address those needs.

“The present focus is on near-to-market opportunities, developing coatings for medical devices, particularly those where long-term exposure leads to a high risk of infection.”

The awards were presented at a prestigious ceremony held at the Mere Golf and Country Club in Cheshire last Thursday.

“Being awarded Bionow Project of the Year in 2004 has helped transform a good biotechnology project into a new start-up company,” said Dr Dobson.

“This year’s honour will boost our efforts to turn a good start-up company into a solid business set to become a major player in this sector.”

Ai2’s Bionow award was one of three presented to University scientists: Biotechnology Project of the Year went to Dr Paul Bishop, while Biotechnology Company of the Year went to EpiStem, based in the University’s Manchester Incubator Building.

Dr Bishop said he was delighted to receive the award and acknowledged the contributions made by his laboratory, colleagues in the University’s School of Pharmacy and Pharmaceutical Sciences and UMIP.

“This award will hopefully provide a springboard for further funding towards the commercial and therapeutic development of this work,” he added.

Dr Linda Magee, head of Bionow and presenter of the awards, said: “England’s northwest is one of the top three bioscience clusters in the UK and this success is testament to the companies and organisations that make up the biotechnology cluster.

“[The industry] employs more than 20,000 people in the northwest; it is only right, therefore, that we celebrate the achievements within this vital sector.”

Aeron Haworth | alfa
Further information:
http://www.manchester.ac.uk

More articles from Life Sciences:

nachricht Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)

nachricht CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>